×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PLX – protalix biotherapeutics, inc. (de) (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PLX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:05 am
plx
Protalix BioTherapeutics (NYSE:PLX) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Protalix BioTherapeutics (NYSE:PLX) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
11/13
06:50 am
plx
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
High
Report
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
11/6
06:50 am
plx
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
Medium
Report
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
11/5
10:50 am
plx
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
11/3
04:30 pm
plx
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
Low
Report
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
10/31
08:31 pm
plx
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
10/28
10:00 am
plx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
10/23
10:00 am
plx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
06:50 am
plx
protalix biotherapeutics, inc. (de)
MISS
Report
-11.0%
protalix biotherapeutics, inc. (de)
8/14/2025
06:50 am
plx
protalix biotherapeutics, inc. (de)
MISS
Report
-5.6%
protalix biotherapeutics, inc. (de)
5/9/2025
06:50 am
plx
protalix biotherapeutics, inc. (de)
MISS
Report
-40.9%
protalix biotherapeutics, inc. (de)
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:35 pm
plx
Form 4 Protalix BioTherapeutics For: Nov 18 Filed by: Bar-Shalev Amos
Low
Report
Form 4 Protalix BioTherapeutics For: Nov 18 Filed by: Bar-Shalev Amos
11/13
06:59 am
plx
Form 10-Q Protalix BioTherapeutics For: Sep 30
High
Report
Form 10-Q Protalix BioTherapeutics For: Sep 30
11/13
06:55 am
plx
Form 8-K Protalix BioTherapeutics For: Nov 13
High
Report
Form 8-K Protalix BioTherapeutics For: Nov 13
11/3
04:44 pm
plx
Form 8-K Protalix BioTherapeutics For: Nov 03
Low
Report
Form 8-K Protalix BioTherapeutics For: Nov 03
10/17
08:09 am
plx
Form 8-K Protalix BioTherapeutics For: Oct 17
Medium
Report
Form 8-K Protalix BioTherapeutics For: Oct 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/17
Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease
65.8%
11/18 Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States 35.8%
6/6 Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States 35.2%
4/13 Form 4 Protalix BioTherapeutics For: Apr 07 Filed by: Schwartz Aharon 21.2%
1/3 Form 3 Protalix BioTherapeutics For: Jan 01 Filed by: Melincoff Gwen A 18.2%
3/23 Form SC 13G Protalix BioTherapeutics Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC 8.3%
4/17 Form S-3 Protalix BioTherapeutics 7.7%
11/27 Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease 7.5%
3/5 Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 7.3%
8/22 Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships 6.2%
11/18 Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States 35.8%
6/6 Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States 35.2%
4/13 Form 4 Protalix BioTherapeutics For: Apr 07 Filed by: Schwartz Aharon 21.2%
1/3 Form 3 Protalix BioTherapeutics For: Jan 01 Filed by: Melincoff Gwen A 18.2%
3/23 Form SC 13G Protalix BioTherapeutics Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC 8.3%
4/17 Form S-3 Protalix BioTherapeutics 7.7%
11/27 Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease 7.5%
3/5 Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 7.3%
8/22 Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships 6.2%
TOP News Decliners
8/8
Form 8-K Protalix BioTherapeutics For: Aug 08
-40.2%
4/30 Form EFFECT Protalix BioTherapeutics -17.2%
2/6 Form 8-K Protalix BioTherapeutics For: Feb 06 -9.0%
3/12 Form 10-K Protalix BioTherapeutics For: Dec 31 -8.4%
3/12 Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results -7.4%
10/4 Form PRE 14A Protalix BioTherapeutics For: Dec 09 -7.2%
5/6 Form 8-K Protalix BioTherapeutics For: May 06 -6.9%
7/29 Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer -6.0%
8/13 Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics -5.7%
8/30 Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American -5.7%
4/30 Form EFFECT Protalix BioTherapeutics -17.2%
2/6 Form 8-K Protalix BioTherapeutics For: Feb 06 -9.0%
3/12 Form 10-K Protalix BioTherapeutics For: Dec 31 -8.4%
3/12 Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results -7.4%
10/4 Form PRE 14A Protalix BioTherapeutics For: Dec 09 -7.2%
5/6 Form 8-K Protalix BioTherapeutics For: May 06 -6.9%
7/29 Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer -6.0%
8/13 Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics -5.7%
8/30 Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: